A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- GREEN MEMORY
- status
- SUSPENDED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 2046
- sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
- conditions
- Alzheimer Disease
- interventions
- DRUG: GV-971; DRUG: Placebo
- start date
- 2020-10-27
- start date type
- ACTUAL
- primary completion date
- 2025-12-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT04520412
- Published
- Aug 20, 2020
- Updated
- Nov 23, 2022
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT04520412
- Categories
- Alzheimer Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials